Evogene Ltd. Files 6-K with Q2 Financials

TL;DR

Evogene dropped Q2 financials on 9/16. Check the numbers.

AI Summary

Evogene Ltd. filed a Form 6-K on September 16, 2024, to furnish unaudited condensed consolidated financial statements for the period ending June 30, 2024. The filing includes financial data as of and for the three and six months ended June 30, 2024 and 2023. Evogene Ltd. is an Israeli company operating in the agriculture chemicals sector.

Why It Matters

This filing provides investors with updated financial performance data for Evogene Ltd., crucial for assessing the company's current financial health and operational progress.

Risk Assessment

Risk Level: low — This is a routine financial filing (6-K) providing updated financial statements, not indicating new significant risks or events.

Key Players & Entities

• Evogene Ltd. (company) — Registrant
• Securities and Exchange Commission (company) — Regulatory body
• June 30, 2024 (date) — Reporting period end date
• September 16, 2024 (date) — Filing date

FAQ

Filing Documents

• zk2432032.htm (6-K) — 21KB
• exhibit_99-1.htm (EX-99.1) — 1005KB
• exhibit_99-2.htm (EX-99.2) — 64KB
• 0001178913-24-003077.txt ( ) — 5199KB
• evgn-20240630.xsd (EX-101.SCH) — 78KB
• evgn-20240630_cal.xml (EX-101.CAL) — 54KB
• evgn-20240630_def.xml (EX-101.DEF) — 115KB
• evgn-20240630_lab.xml (EX-101.LAB) — 594KB
• evgn-20240630_pre.xml (EX-101.PRE) — 248KB
• zk2432032_htm.xml (XML) — 932KB

From the Filing

Evogene Ltd. - 1574565 - 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-36187 EVOGENE LTD. ( Translation of Registrant's Name into English) 13 Gad Feinstein Street Park Rehovot , Rehovot 7638517 , Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F CONTENTS This Report of Foreign Private Issuer on Form 6-K, or Form 6-K, is being furnished by Evogene Ltd., or Evogene, to the Securities and Exchange Commission, or SEC, for the sole purposes of: (i) furnishing, as Exhibit 99.1 to this Form 6-K, unaudited condensed consolidated financial statements of Evogene as of and for the six-month period ended June 30, 2024; and (ii) furnishing, as Exhibit 99.2 to this Form 6-K, Evogene's Operating and Financial Review and Prospects, which discusses and analyzes Evogene's financial condition and results of operations as of, and for the six-month period ended, June 30, 2024 . The contents of Exhibits 99.1 and 99.2 to this Form 6-K are incorporated by reference in the registration statements on Form F-3 (SEC File No. 333-277565), and Form S-8 (SEC File Nos. 333-193788, 333-201443, 333-203856 and 333-259215) of Evogene, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. EXHIBIT INDEX Exhibit No. Description 99.1 Unaudited Condensed Consolidated Financial Statements as of, and for the Six Months Ended, June 30, 2024. 99.2 Operating and Financial Review and Prospects as of, and for the six month ended, June 30, 2024. 101 Interactive data files pursuant to Rule 405 of Regulation S-T: (i) Consolidated Interim Statements of Financial Position, (ii) Consolidated Interim Statements of Profit or Loss, (iii) Consolidated Interim Statements of Changes in Equity; (iv) Consolidated Interim Statements of Cash Flows, and (v) Notes to Interim Consolidated Financial Statements. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: September 16, 2024 EVOGENE LTD. (Registrant) By: /s/ Yaron Eldad Yaron Eldad Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR